Evidence map›Paper›PMID 32297448›Full record

ArticleThe oncologist2020

Subtype-Guided

Siyu Wu, Yujie Wang, Jianwei Li, Na Zhang, Miao Mo, Suzanne Klimberg, Virginia Kaklamani, Alexandre Cochet, Zhiming Shao, Jingyi Cheng and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Value ofEJNMMI research · 2021
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Siyu Wu *Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Yujie Wang *Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Jianwei LiDepartment of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Na ZhangDepartment of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Miao MoClinical Statistics Center, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Suzanne KlimbergDivision of Breast Surgical Oncology, Department of Surgery, University of Texas Medical Branch, Galveston, Texas, USA.
Virginia KaklamaniDivision of Hematology and Oncology, Northwestern University, Chicago, Illinois, USA.
Alexandre CochetDepartment of Nuclear Medicine, Centre Georges-François Leclerc, University Hospital of Dijon, Dijon, France.
Zhiming ShaoDepartment of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Jingyi ChengDepartment of Nuclear Medicine, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Guangyu LiuDepartment of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China.
Fudan University Shanghai Cancer Center · CNCentre Georges François Leclerc · FRNorthwestern University · USShanghai Jiao Tong University · CNThe University of Texas Medical Branch at Galveston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe purpose of this study was to investigate the value of

methodsOne hundred thirty-three patients with breast cancer with biopsy-confirmed nodal metastasis were prospectively enrolled.

resultsWith the cutoff value of 2.5 for baseline SUV

conclusionApplication of the subtype-guided IMPLICATIONS FOR PRACTICE: This feasibility study showed that

Indexed as

Breast NeoplasmsFluorodeoxyglucose F18Feasibility StudiesFemaleHumansNeoadjuvant TherapyPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsFluorodeoxyglucose F18Radiopharmaceuticals18[F]-fluorodeoxyglucose positron emission tomography/computed tomographyAxillary surgeryNeoadjuvant chemotherapyResponseSubtype-guided

Identifiers

PMID32297448
PMCPMC7160406
OpenAlexW2995775814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.